Research & Innovation in Microbiological Quality Control for ATMP and Medical Technologies
At Sure Laboratories, our research projects focus on improving microbiological quality control and validation within the ATMP, microbial and medical device industries. ATMPs (Advanced Therapy Medicinal Products) include innovative therapies based on genes, cells and tissue engineering, where microbiological control and GMP compliance are essential throughout development and manufacturing. Together with manufacturers, research organisations and industry partners, we work on practical solutions for contamination control, rapid microbiological testing, sterilization validation and microbiological risk management. Our research is driven by the challenges faced by QC and QA teams in regulated environments, with a strong focus on compliance, reliability and real-world application. By combining laboratory expertise with industry knowledge, we support collaborative projects that help bring safe and compliant products to market and patients more efficiently.
ATMP XB project
Sure Laboratories is partner in the EU co-funded ATMP XB project, aiming to strengthen the Flemish–Dutch border region as a leading hub for ATMP research and development by providing reliable infrastructure, fostering innovation, building knowledge and creating strong cross-border collaboration.
ATMPs (advanced therapy medicinal products) include cell and gene therapies that use living cells or genetically modified material to treat severe or currently incurable diseases such as cancer, rare genetic disorders and chronic inflammatory conditions.
Through collaboration between educational institutions, hospitals and companies, ATMP XB focuses on improving production, quality control, technology development and specialized training to help bring these innovative therapies to patients faster and more safely.
BioNanoGel Kick Off
Wednesday October 18th 2023, the Interreg Dutch-German project BioNanoGel kicked-off. The participants aim to develop improved hydrogels to treat bladder and sinus diseases. All participants have a trackrecord in development, testing and research in the field of urology and sinus surgery. In addition, the experience and development of new dosage forms and preparations for clinical tests were the main reasons to grant the Interreg subsidy to the consortium. The participants are INVITE GmbH, Oxprotect GmbH, Universitair Ziekenhuis Münster, Sure Laboratories B.V., Noviotissue B.V., RadboudUMC en the consortium lead, BioMed Elements B.V.
We hope to deliver a first clinical validation of new hydrogels for chronic sinusitis, cystisitus interstialis and stress incontinence which allows higher quality of life for patients. The BioNanGel project is being carried out within the framework of the Interreg VI program Germany-Netherlands and is co-financed with € 1,846,528.07 euros by the European Union, the MWIKE NRW, the Ministry of Economic Affairs and Climate Policy and the provinces of Gelderland and North Brabant (www.deutschland -nederland.eu).
BioNanoGel Kick Off
Op woensdag 18 oktober 2023 was de aftrap voor het Interreg Nederland-Duitsland project ‘BioNanoGel’. Gezamenlijk hebben de partners als doel om betere hydrogels te ontwikkelen voor aandoeningen aan de blaas en bijholte. De partners hebben jarenlange ervaring met het ontwikkelen, testen en onderzoek doen in het veld van urologie en bijholtechirurgie. De ervaring met de ontwikkeling van nieuwe doseringsvormen en voorbereiding van klinische testen, waren redenen om de aanvraag van het consortium positief te beschikken. Het einde van het project moet een eerste klinische validatie opleveren van de nieuwe hydrogels voor chronische bijholteontsteking, blaaspijn syndroom en stressincontinentie waardoor uiteindelijk patiënten een hogere kwaliteit van leven krijgen.
De projectpartners bestaan uit INVITE GmbH, Oxprotect GmbH, Universitair Ziekenhuis Münster, Sure Laboratories B.V., Noviotissue B.V., RadboudUMC en penvoerder BioMed Elements B.V.
Het BioNanoGel project wordt uitgevoerd in het kader van het Interreg VI-programma Duitsland-Nederland en wordt met 1.846.528,07 euro medegefinancierd door de Europese Unie, het MWIKE NRW, het Ministerie van EZK en de provincies Gelderland en Noord-Brabant (www.deutschland-nederland.eu).
Image above: Project representatives: Dr. Bas van den Broek (BioMed Elements), PD dr. Achim Beule (Universitair Ziekenhuis Münster), Christin Jungnitsch (Interreg FLC), Piet Boomsma (Interreg Programmamanagement), Pia Simon (Interreg Programmamanagement), Tonny Voermans (Noviotissue), dr. Ildikó Terebesi (INVITE), dr. Martin Brodde (OxProtect) en Frank van der Zanden (Sure Laboratories). Dr. Dick Janssen (RadboudUMC) en dr. Benedict Brücher (Universitair Ziekenhuis Münster) were not present when this picture was taken / staan niet op de foto.
